Effect of Sodium Glucose Co-transporter Type 2 Inhibitors on The Infract size among Diabetic Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Document Type : Original Article

Authors

1 Lecturer of cardiology faculty of medicine zagazig university

2 The Department of Cardiology, faculty of medicine ,Zagazig University, Zagazig, Egypt.

3 Cardiology department al-ahrar teaching hospital

4 A. professor of cardiology department faculty of medicine zagazig university

Abstract

Background: Myocardial ischemia causes cell death, which sets off an inflammatory cascade that eventually leads to the formation of scars.Sodium-glucose co-transporter-2 inhibitors(SGLT2I) used in the management of patients with type 2 diabetes.

Aim: Is to evaluate the long-term treatment with SGLT2I on decreasing the infarct size in STEMI diabetic patientswho undergoing primary percutaneous coronary intervention.

methods: This Comparative study included 30 patients who were admitted with STEMI undergoing Primary PCI. Patients were divided equally into group(1) : diabetic patients not on SGLT2I & group 2 :diabetic patients on SGLT2I for more than 6 months. Baseline characteristics, echocardiographic parameters , angiographic and procedural data, medication use, and outcome data were recorded prospectively.

Results: Regarding biomarkers, hs-TnI levels were significantly higher in non SGLT2I group compared to SGLT2I group (P<0.05).Furthermore, the angiography finding, TIMI flow after PCI was significantly improved in SGLT2I group compared to non SGLT2I group P=0.029. On hospital discharge, ST resolution and Ejection Fraction(EF) were significantly higher in SGLT2I group compared to non SGLT2I group P<0.001 ,also WMSI on hospital discharge was significantly higher in non SGLT2I group compared to SGLT2I group P=0.007 . Mitral regurgitation was significantly different between both groups, being significantly improved in SGLT2I group compared to non SGLT2I group P=0.003. Baseline EF, WMSI and mitral regurgitation were insignificantly different between both groups.

Conclusion: Diabetic patients with STEMI undergoing PPCI and treated with SGLT2I exhibited significantly decreased the infract size and improved cardiovascular outcomes compared to those not on SGLT2Itherapy.

Keywords

Main Subjects

Zagazig University Medical Journal
Volume 30, Issue 1.3
March and April 2024
Pages 336-346

Files

Share

How to cite

Statistics